Skip to main content

Table 7 Effect of FVBM , F18 bioactive compound and atorvastatin on plasma LDL-C, HDL-C and VLDL-C in Triton WR-1339 induced hyperlipidemic rats after 18 hours of treatment

From: Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait

Group LDL-C HDL-C VLDL-C
NC 35.5 ± 1.12* 27.5 ± 0.99 12 ± 0.67
HLC 280.12 ± 4.36* 22.28 ± 0.56 48.26 ± 1.45
(+646.66%)a (−20%)a (+300.04%)a
FVT-1 81.15 ± 2.19* 26.63 ± 0.74 19.09 ± 0.81
(−71.07%)a (+19.3%)a (−60.41%)a
FVT-2 39.5 ± 1.37* 29.7 ± 1.15 13.08 ± 0.64
(−85.89%)a (+35%)a (−71.40%)a
CT 43.26 ± 1.25* 28.2 ± 1.14 12.54 ± 0.63
(−84.55%)a (+28.18%)a (−74.01%)a
AT 37.88 ± 1.18* 28.4 ± 1.15 11.72 ± 0.52
(−86.47%)a (+29.09%)a (−75.71%)a
  1. *Values are mean (mg/dl) ± SD from LDL-C, HDL-C and VLDL-C, isolated from plasma of 5 rats in each group.
  2. NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18 bioactive compound/rat and AT, given 1 mg atorvastatin/rat once.
  3. Significantly different from NC at ap < 0.001.
  4. Significantly different from HLC at ap < 0.001.